140 related articles for article (PubMed ID: 1720278)
41. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
[TBL] [Abstract][Full Text] [Related]
42. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Barista I; Tekuzman G; Firat D; Baltali E; Kansu E; Kars A; Ozisik Y; Ruacan S; Uzunalimoğlu B; Karaağaoğlu E
Jpn J Cancer Res; 1994 Dec; 85(12):1200-7. PubMed ID: 7531679
[TBL] [Abstract][Full Text] [Related]
43. Failure of conventional chemotherapy in aggressive lymphomas.
Cunningham D; Hepplestone A; Gilchrist NL; Dagg JH; Evans IL; Soukop M
Postgrad Med J; 1987 Jan; 63(735):11-5. PubMed ID: 2444960
[TBL] [Abstract][Full Text] [Related]
44. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
45. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
46. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
47. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
48. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
[TBL] [Abstract][Full Text] [Related]
49. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.
Bos GM; van Putten WL; van der Holt B; van den Bent M; Verdonck LF; Hagenbeek A
Ann Oncol; 1998 Feb; 9(2):191-4. PubMed ID: 9553665
[TBL] [Abstract][Full Text] [Related]
50. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
51. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Korfel A; Thiel E
Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
[TBL] [Abstract][Full Text] [Related]
52. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
53. CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.
Vose JM; Weisenburger DD; Lynch JC; Bierman PJ; Chan JC; Bast M; Aoun P; Bociek G; Greiner T; Armitage JO;
Leuk Lymphoma; 2002 Apr; 43(4):799-804. PubMed ID: 12153167
[TBL] [Abstract][Full Text] [Related]
54. Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucenie (GIMURELL) study.
Cabras MG; Mamusa AM; Vitolo U; Freilone R R; Dessalvi P; Orsucci L; Tonso A; Levis A; Liberati M; Lay G; Angelucci E
Leuk Lymphoma; 2009 Sep; 50(9):1475-81. PubMed ID: 19579074
[TBL] [Abstract][Full Text] [Related]
55. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
56. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
57. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
58. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
[TBL] [Abstract][Full Text] [Related]
59. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
[TBL] [Abstract][Full Text] [Related]
60. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
